Report Overview

The Global Leukemia Therapeutics market size stood at USD 12.3 billion in 2019 and is expected to rise to USD 22.24 billion by the end of 2028 exhibiting a CAGR of approximately 6.8% during the forecast period.

According to the Globocan 2020 report on Sweden, Leukemia is the twelfth common cancer, accounting for 2.1% among all the registered cancer cases. This is the ninth most common reason for deaths out of all cancer deaths in the .

Leukemia is a cancer of the blood cells that occur due to abnormal proliferation of White Blood Cells. While the exact reason for Leukemia still remains at large, it is attributed to a combination of genetic and environmental factors. Since Acute Lymphoblastic Leukemia increasingly occurs in children, the market is always on the booming end which provides the pharmaceutical manufacturers innumerable opportunities to revolutionize the drug market.



Market Drivers

Sweden Leukemia drugs market is driven by the increasing prevalence of the disease in the country. Rise in death incidences from Leukemia in the country also propel market growth. Increased Government involvement with a rise in per capita spending on healthcare also act as essential drivers for market growth. Increased funding for Research and Development in the area also contributes for market growth.